Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Helicobacter pylori | 8 | 2020 | 9 | 0.650 |
Why?
|
| Helicobacter Infections | 7 | 2019 | 8 | 0.460 |
Why?
|
| Virulence | 3 | 2020 | 25 | 0.220 |
Why?
|
| Virulence Factors | 2 | 2020 | 18 | 0.220 |
Why?
|
| Esophageal Diseases | 1 | 2001 | 3 | 0.200 |
Why?
|
| Triazoles | 1 | 2001 | 15 | 0.200 |
Why?
|
| Fluconazole | 1 | 2001 | 17 | 0.200 |
Why?
|
| Candidiasis | 1 | 2001 | 15 | 0.190 |
Why?
|
| Immunocompromised Host | 1 | 2001 | 33 | 0.190 |
Why?
|
| Pyrimidines | 1 | 2001 | 29 | 0.190 |
Why?
|
| Antifungal Agents | 1 | 2001 | 40 | 0.190 |
Why?
|
| Hepatitis C | 2 | 2017 | 37 | 0.190 |
Why?
|
| Pancreatitis | 1 | 2000 | 8 | 0.190 |
Why?
|
| Stomach Diseases | 1 | 2020 | 2 | 0.180 |
Why?
|
| Peptic Ulcer | 2 | 2019 | 4 | 0.180 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 27 | 0.180 |
Why?
|
| Hepacivirus | 1 | 2020 | 37 | 0.180 |
Why?
|
| Hepatitis C, Chronic | 1 | 2020 | 26 | 0.180 |
Why?
|
| Hepatitis B | 2 | 2017 | 123 | 0.170 |
Why?
|
| Gastritis | 1 | 2019 | 3 | 0.170 |
Why?
|
| Risk Factors | 6 | 2020 | 1431 | 0.150 |
Why?
|
| Stomach Neoplasms | 4 | 2002 | 5 | 0.150 |
Why?
|
| Prevalence | 7 | 2020 | 1149 | 0.150 |
Why?
|
| Humans | 18 | 2020 | 14077 | 0.140 |
Why?
|
| African Americans | 2 | 2004 | 47 | 0.140 |
Why?
|
| Male | 10 | 2020 | 6489 | 0.140 |
Why?
|
| Middle Aged | 9 | 2020 | 3425 | 0.130 |
Why?
|
| Aged | 6 | 2020 | 1650 | 0.130 |
Why?
|
| Genotype | 4 | 2020 | 430 | 0.120 |
Why?
|
| Health Facility Closure | 1 | 2014 | 5 | 0.120 |
Why?
|
| Hospital Units | 1 | 2014 | 7 | 0.120 |
Why?
|
| Adult | 8 | 2020 | 5664 | 0.120 |
Why?
|
| Female | 9 | 2020 | 8751 | 0.120 |
Why?
|
| Hospitals, Public | 1 | 2014 | 44 | 0.110 |
Why?
|
| Antiviral Agents | 3 | 2020 | 107 | 0.110 |
Why?
|
| South Africa | 11 | 2020 | 7312 | 0.110 |
Why?
|
| Glutathione | 1 | 2011 | 4 | 0.100 |
Why?
|
| Pancreatitis, Chronic | 1 | 2011 | 4 | 0.100 |
Why?
|
| Sulfates | 1 | 2011 | 7 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2020 | 184 | 0.090 |
Why?
|
| Antigens, Bacterial | 2 | 2019 | 32 | 0.090 |
Why?
|
| Hypoparathyroidism | 1 | 1989 | 1 | 0.080 |
Why?
|
| Adolescent | 5 | 2019 | 2858 | 0.080 |
Why?
|
| Africa South of the Sahara | 2 | 2017 | 328 | 0.070 |
Why?
|
| Coinfection | 2 | 2017 | 268 | 0.060 |
Why?
|
| Base Pairing | 1 | 2004 | 1 | 0.060 |
Why?
|
| DNA Transposable Elements | 1 | 2004 | 4 | 0.060 |
Why?
|
| Acute Disease | 2 | 2000 | 105 | 0.060 |
Why?
|
| Sarcoidosis | 1 | 1984 | 8 | 0.060 |
Why?
|
| Lung Diseases | 1 | 1984 | 29 | 0.060 |
Why?
|
| Wolinella | 1 | 2003 | 1 | 0.060 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2003 | 7 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 26 | 0.060 |
Why?
|
| Biopsy | 2 | 2019 | 37 | 0.060 |
Why?
|
| Evolution, Molecular | 2 | 2020 | 60 | 0.060 |
Why?
|
| Geography | 2 | 2020 | 60 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2003 | 32 | 0.060 |
Why?
|
| DNA, Bacterial | 2 | 2019 | 53 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 184 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2002 | 8 | 0.050 |
Why?
|
| Developed Countries | 1 | 2002 | 23 | 0.050 |
Why?
|
| Consumer Product Safety | 1 | 2001 | 1 | 0.050 |
Why?
|
| Voriconazole | 1 | 2001 | 4 | 0.050 |
Why?
|
| Bacterial Proteins | 2 | 2019 | 117 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 449 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2001 | 263 | 0.050 |
Why?
|
| Environment | 1 | 2000 | 21 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 10 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2020 | 19 | 0.050 |
Why?
|
| Platelet Count | 1 | 2020 | 14 | 0.050 |
Why?
|
| Ribavirin | 1 | 2020 | 15 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2020 | 15 | 0.050 |
Why?
|
| Endoscopy | 1 | 2020 | 4 | 0.050 |
Why?
|
| Urea | 1 | 2020 | 3 | 0.050 |
Why?
|
| Breath Tests | 1 | 2020 | 3 | 0.050 |
Why?
|
| ROC Curve | 1 | 2020 | 47 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2020 | 4 | 0.050 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 22 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 220 | 0.040 |
Why?
|
| Nigeria | 1 | 2020 | 40 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 48 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 72 | 0.040 |
Why?
|
| Phenotype | 1 | 2020 | 144 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 78 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 271 | 0.040 |
Why?
|
| Phylogeny | 1 | 2020 | 231 | 0.040 |
Why?
|
| Stomach | 1 | 2019 | 6 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 260 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2019 | 21 | 0.040 |
Why?
|
| Developing Countries | 1 | 2002 | 385 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2000 | 464 | 0.040 |
Why?
|
| Young Adult | 2 | 2019 | 2357 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2001 | 867 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 532 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2000 | 186 | 0.040 |
Why?
|
| Fibrosis | 1 | 2017 | 11 | 0.040 |
Why?
|
| Mass Vaccination | 1 | 2017 | 11 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2017 | 47 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2020 | 767 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 405 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2017 | 107 | 0.030 |
Why?
|
| Radiography | 2 | 1989 | 80 | 0.030 |
Why?
|
| Mass Screening | 1 | 2017 | 242 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 265 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2017 | 467 | 0.030 |
Why?
|
| Private Sector | 1 | 2014 | 44 | 0.030 |
Why?
|
| Base Sequence | 2 | 2004 | 149 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2004 | 263 | 0.030 |
Why?
|
| Xenobiotics | 1 | 2011 | 4 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 2011 | 12 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 64 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 217 | 0.020 |
Why?
|
| HIV Infections | 2 | 2017 | 4946 | 0.020 |
Why?
|
| Phosphorus | 1 | 1989 | 1 | 0.020 |
Why?
|
| Basal Ganglia Diseases | 1 | 1989 | 2 | 0.020 |
Why?
|
| Magnesium | 1 | 1989 | 6 | 0.020 |
Why?
|
| Calcinosis | 1 | 1989 | 11 | 0.020 |
Why?
|
| Africa | 2 | 2001 | 360 | 0.020 |
Why?
|
| Calcium | 1 | 1989 | 49 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 1377 | 0.020 |
Why?
|
| Lithuania | 1 | 2004 | 2 | 0.020 |
Why?
|
| Gambia | 1 | 2004 | 13 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1984 | 2 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1984 | 2 | 0.020 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1984 | 12 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1984 | 63 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 180 | 0.010 |
Why?
|
| Lung | 1 | 1984 | 70 | 0.010 |
Why?
|
| Helicobacter | 1 | 2003 | 1 | 0.010 |
Why?
|
| Pneumonia | 1 | 1984 | 127 | 0.010 |
Why?
|
| Dyspepsia | 1 | 2002 | 1 | 0.010 |
Why?
|
| Germany | 1 | 2002 | 6 | 0.010 |
Why?
|
| Parasitic Diseases | 1 | 2002 | 2 | 0.010 |
Why?
|
| Australia | 1 | 2002 | 46 | 0.010 |
Why?
|
| Stomach Ulcer | 1 | 2001 | 1 | 0.010 |
Why?
|
| Duodenal Ulcer | 1 | 2001 | 2 | 0.010 |
Why?
|
| Amino Acid Isomerases | 1 | 2000 | 1 | 0.010 |
Why?
|
| Biological Specimen Banks | 1 | 2000 | 3 | 0.010 |
Why?
|
| Bacterial Toxins | 1 | 2000 | 3 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 2000 | 44 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2000 | 3 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 2000 | 4 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 2000 | 23 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2000 | 104 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2000 | 169 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 299 | 0.010 |
Why?
|
| Biomarkers | 1 | 2000 | 322 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2002 | 1675 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2000 | 1131 | 0.010 |
Why?
|
| Infant | 1 | 2002 | 2145 | 0.010 |
Why?
|
| Child | 1 | 2002 | 2180 | 0.010 |
Why?
|